As reactive gliosis is present in DR (40–42), these results might have new therapeutic implications such as novel strategies for targeting DR associated with T1DM or T2DM based on the specific induction of the M2 response in the retina through sp2-IGL-mediated increase in Arginase-1. The gene discussed is SP2; the disease is type 2 diabetes mellitus.